Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse

Background:

Not enough evidence exists to compare buprenorphine–naloxone with extended-release naltrexone for treating opioid use disorder.

Objective:

To evaluate the cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone.

Design:

Cost-effectiveness analysis alongside a previously reported randomized clinical trial of 570 adults in 8 U.S. inpatient or residential treatment programs.

Data Sources:

Study instruments.

Target Population:

Adults with opioid use disorder.

Time Horizon:

24-week intervention with an additional 12 weeks of observation.

Perspective:

Health care sector and societal.

Interventions:

Buprenorphine–naloxone and extended-release naltrexone.

Outcome Measures:

Incremental costs combined with incremental quality-adjusted life-years (QALYs) and incremental time abstinent from opioids.

Results of Base-Case Analysis:

Use of the health care sector perspective and a willingness-to-pay threshold of $100 000 per QALY showed buprenorphine–naloxone to be preferable to extended-release naltrexone in 97% of bootstrap replications at 24 weeks and in 85% at 36 weeks. Similar results were obtained with incremental time abstinent from opioids as an outcome and with use of the societal perspective.

Results of Sensitivity Analysis:

The base-case results were sensitive to the cost of the 2 treatments and the success of randomized treatment initiation.

Limitation:

Relatively short follow-up for a chronic condition, substantial missing data, no information on patient out-of-pocket and social service costs.

Conclusion:

Buprenorphine–naloxone is preferred to extended-release naltrexone as first-line treatment when both options are clinically appropriate and patients require detoxification before initiating extended-release naltrexone.

Primary Funding Source:

National Institute on Drug Abuse, National Institutes of Health.

https://ift.tt/2rFQrL3